ReviewMolecules (Basel, Switzerland)2019
Advances in Biosynthesis, Pharmacology, and Pharmacokinetics of Pinocembrin, a Promising Natural Small-Molecule Drug.
Review in Molecules (Basel, Switzerland), 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 48 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
48 citing papers in PubMed, 107 citations in OpenAlex.
- Preclinical Pharmacological Actions of Alpinetin and Pinocembrin-A Comparative Review.Pharmaceuticals (Basel, Switzerland) · 2026Review
- Recent Progress on Polyphenols of Malaysian Honey and Their Molecular Mechanism Pathways in Cancer-A Comprehensive Review.International journal of molecular sciences · 2026Review
- Takeda G Protein-Coupled Receptor 5 and Peroxisome Proliferator-Activated Receptor-Gamma Activation by Pinocembrin and Pinostrobin Isolated fromInternational journal of molecular sciences · 2026Article
- Protective effect of pinocembrin on zearalenone-induced hepatotoxicity via PI3K/AKT and NRF2 signaling in albino mice.Turkish journal of biology = Turk biyoloji dergisi · 2026Article
- Histone deacetylase HDAC7 restricts CD8 + T cell tumor infiltration and limits immunotherapy sensitivity in bladder cancer: reversal by pinocembrin.Journal of experimental & clinical cancer research : CR · 2025Article
- Pinocembrin as a novel anti-cancer agent: Exploring preclinical evidence along with therapeutic potential.World journal of experimental medicine · 2025Review
- Pinocembrin Isolated from Nigerian Propolis Prevents Elevation of Cytokines Implicated in the Aetiology of Diabetic Retinopathy in Rat Models of Diabetes Mellitus.Archives of Razi Institute · 2025Article
- Bioactive Molecules from Tropical American Plants: Potential Anti-Inflammatory Agents for Cytokine Storm Management.Molecules (Basel, Switzerland) · 2025Review
- From bench to bedside: therapeutic potential of natural antioxidants in diabetic neuropathy.Frontiers in cell and developmental biology · 2025Review
- Mechanistic Insights into Flavonoid Subclasses as Cardioprotective Agents Against Doxorubicin-Induced Cardiotoxicity: A Comprehensive Review.Drug design, development and therapy · 2025Review
- Potential Interaction of Pinocembrin with Drug Transporters and Hepatic Drug-Metabolizing Enzymes.Pharmaceuticals (Basel, Switzerland) · 2025Article
- New reverse sum Revan indices for physicochemical and pharmacokinetic properties of anti-filovirus drugs.Frontiers in chemistry · 2024Article
- Inhibitory Effect of (2Advances in pharmacological and pharmaceutical sciences · 2024Article
- In Vitro Anti-Inflammatory Activity of Methyl Derivatives of Flavanone.Molecules (Basel, Switzerland) · 2023Article
- Article
- Neuroprotective Potential of Flavonoids in Brain Disorders.Brain sciences · 2023Review
- Review
- Article
- Potential of natural flavonols and flavanones in the treatment of ulcerative colitis.Frontiers in pharmacology · 2023Review
- Physicochemical Profile, Antioxidant and Antimicrobial Activities of Honeys Produced in Minas Gerais (Brazil).Antibiotics (Basel, Switzerland) · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
Abstract
Pinocembrin is one of the most abundant flavonoids in propolis, and it may also be widely found in a variety of plants. In addition to natural extraction, pinocembrin can be obtained by biosynthesis. Biosynthesis efficiency can be improved by a metabolic engineering strategy and a two-phase pH fermentation strategy. Pinocembrin poses an interest for its remarkable pharmacological activities, such as neuroprotection, anti-oxidation, and anti-inflammation. Studies have shown that pinocembrin works excellently in treating ischemic stroke. Pinocembrin can reduce nerve damage in the ischemic area and reduce mitochondrial dysfunction and the degree of oxidative stress. Given its significant efficacy in cerebral ischemia, pinocembrin has been approved by China Food and Drug Administration (CFDA) as a new treatment drug for ischemic stroke and is currently in progress in phase II clinical trials. Research has shown that pinocembrin can be absorbed rapidly in the body and easily cross the blood-brain barrier. In addition, the absorption/elimination process of pinocembrin occurs rapidly and shows no serious accumulation in the body. Pinocembrin has also been found to play a role in Parkinson's disease, Alzheimer's disease, and specific solid tumors, but its mechanisms of action require in-depth studies. In this review, we summarized the latest 10 years of studies on the biosynthesis, pharmacological activities, and pharmacokinetics of pinocembrin, focusing on its effects on certain diseases, aiming to explore its targets, explaining possible mechanisms of action, and finding potential therapeutic applications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.